SELECT * FROM `stock_list` WHERE `symbol` = "OVID" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1
SELECT * FROM `stock_list` where symbol='OVID' AND exchange = 'NAS' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "OVID" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 OVID (Ovid Therapeutics) Asset Turnover
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (NAS:OVID) » Definitions » Asset Turnover

Ovid Therapeutics (Ovid Therapeutics) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Ovid Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Ovid Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.14 Mil. Ovid Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $134.53 Mil. Therefore, Ovid Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Ovid Therapeutics's annualized ROE % for the quarter that ended in Dec. 2023 was -64.82%. It is also linked to ROA % through Du Pont Formula. Ovid Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -45.56%.


Ovid Therapeutics Asset Turnover Historical Data

The historical data trend for Ovid Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovid Therapeutics Asset Turnover Chart

Ovid Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only - 0.16 1.54 0.01 -

Ovid Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ovid Therapeutics's Asset Turnover

For the Biotechnology subindustry, Ovid Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovid Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's Asset Turnover falls into.



Ovid Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Ovid Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.392/( (155.266+144.027)/ 2 )
=0.392/149.6465
=0.00

Ovid Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0.142/( (125.029+144.027)/ 2 )
=0.142/134.528
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Ovid Therapeutics  (NAS:OVID) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Ovid Therapeutics's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-61.288/94.5445
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-61.288 / 0.568)*(0.568 / 134.528)*(134.528/ 94.5445)
=Net Margin %*Asset Turnover*Equity Multiplier
=-10790.14 %*0.0042*1.4229
=ROA %*Equity Multiplier
=-45.56 %*1.4229
=-64.82 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Ovid Therapeutics's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-61.288/134.528
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-61.288 / 0.568)*(0.568 / 134.528)
=Net Margin %*Asset Turnover
=-10790.14 %*0.0042
=-45.56 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Ovid Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovid Therapeutics (Ovid Therapeutics) Business Description

Traded in Other Exchanges
Address
441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Executives
Jason Tardio officer: Chief Commercial Officer 1460 BROADWAY, NEW YORK NY 10036
Takeda Pharmaceuticals U.s.a., Inc. 10 percent owner ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Kevin Joseph Fitzgerald director C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Amit Rakhit officer: CMO and PMO C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Robert Michael Poole director 200 W. HIGHLAND DR., #303, SEATTLE WA 98119
Jeffrey A Rona officer: Chief Business Officer 500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeremy M Levin director, 10 percent owner, officer: CEO
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Thomas Michael Perone officer: SVP, General Counsel 1460 BROADWAY, NEW YORK NY 10036
Karen Bernstein director C/O VITAE PHARMACEUTICLS, INC., 502 WEST OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Millennium Pharmaceuticals Inc 10 percent owner 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Douglas E Williams director C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Ana Ward officer: SVP and General Counsel C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Timothy Daly officer: VP, Finance & Corp. Controller 20 KINGSBRIDGE ROAD, PISCATAWAY NJ 08854